You are here: Industry Insights > Dr Reddy

News List

US top court denies Indivior’s request on suboxone, Dr Reddy’s gains Hyderabad expressbpd
February 21, 2019
Indivior is in legal battle against the launch of copycat version of its opioid addiction treatment by competitors including Dr Reddy’s Laboratories in the US market
Indivior shares soar as US judge rules against Dr Reddy pharmafile
July 17, 2018
Shares in the London listed addiction specialist Indivior surged in price today, as the Indian pharmaceutical company Dr Reddy’s Laboratories was blocked from selling generic versions of Indivior’s bestselling opioid addiction treatment, Suboxone Film, in
Dr Reddy's just-approved opioid dependence generic blocked over US patent dispute pharmafile
June 22, 2018
Dr Reddy’s Laboratories has taken two steps forward an one step back after its generic version of Suboxone Film (buprenorphine/naloxone) secured FDA approval for the treatment of opioid dependence,
Dr Reddy’s Srikakulam unit clears US FDA audit expressbpd
September 29, 2017
The US Food and Drug Administration (US FDA) has cleared pharma major Dr Reddy’s Laboratories Ltd’s formulation Srikakulam Plant (SEZ) Unit I in Andhra Pradesh from its recent audit.
South Korea’s Mezzion Pharma files suit against Dr Reddy’s in US financialexpress
February 07, 2017
Hyderabad-based Dr Reddy’s has, however, said it is yet to receive any ‘legal papers’.

Previous page 1 2 3 4 5 Next page